Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Prime Medicine, Inc.

Prime Medicine, Inc. (PRME) Stock Overview

Explore Prime Medicine, Inc.’s financial performance, market position, analyst ratings, and future outlook.

PRME●NASDAQ
HealthcareBiotechnology
$3.00
$0.05(1.69%)
U.S. Market is Open · 12:02

Prime Medicine, Inc. (PRME)

Meyka AI Score

Z

Key Financials

Market Cap543.7M
P/E Ratio-2.43
EPS (TTM)$-1.23
ROE-1.89%
Fundamental Analysis

AI Price Forecasts

1 Month$1.89
3 Months$6.33
1 Year Target$4.43

PRME Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Prime Medicine, Inc. (NASDAQ: PRME) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Prime Medicine, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of PRME on the NASDAQ shows an RSI of 42.55, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $4.43 for the NASDAQ listing.

Key metrics behind Prime Medicine, Inc.'s NASDAQ-traded stock include a P/E ratio of -2.43 and a market capitalization of 543.7M. Combined with our AI analysis, these give both institutional and retail investors a clear view of PRME on the NASDAQ.

Price Performance (NASDAQ: PRME)

1-Day Change
2.03%
5-Day Change
-3.22%
1-Month Change
-12.24%
3-Month Change
-17.98%
6-Month Change
-29.67%
Year-to-Date (YTD) Change
-13.26%
1-Year Change
-26.41%
3-Year Change
-78.94%
5-Year Change
-80.42%
All-Time (Max) Change
-80.42%

Contact Information

https://www.primemedicine.com
617-564-0013
60 First Street, Cambridge, MA, 02139

Company Facts

1,460 Employees
IPO DateOct 20, 2022
CountryUS
Actively Trading

Frequently Asked Questions